| Identification |
| Name: | Benzamide,N-(1-methylethyl)-4-[(2-methylhydrazinyl)methyl]- |
| Synonyms: | Benzamide,N-(1-methylethyl)-4-[(2-methylhydrazino)methyl]- (9CI); p-Toluamide,N-isopropyl-a-(2-methylhydrazino)-(7CI,8CI); 1-Methyl-2-[p-(isopropylcarbamoyl)benzyl]hydrazine;4-[(2-Methylhydrazino)methyl]-N-isopropylbenzamide; CB 400-497; Ibenzmethyzine;MIH; N-Isopropyl-a-(2-methylhydrazino)-p-toluamide;Procarbazine; p-(2-Methylhydrazinomethyl)-N-isopropylbenzamide |
| CAS: | 671-16-9 |
| EINECS: | 211-582-2 |
| Molecular Formula: | C12H19 N3 O |
| Molecular Weight: | 221.34 |
| InChI: | InChI=1/C12H19N3O/c1-9(2)15-12(16)11-6-4-10(5-7-11)8-14-13-3/h4-7,9,13-14H,8H2,1-3H3,(H,15,16) |
| Molecular Structure: |
![(C12H19N3O) Benzamide,N-(1-methylethyl)-4-[(2-methylhydrazino)methyl]- (9CI); p-Toluamide,N-isopropyl-a-(2-methy...](https://img1.guidechem.com/chem/e/dict/34/671-16-9.jpg) |
| Properties |
| Density: | 1.035 g/cm3 |
| Stability: | Stable in light, slowly oxidized in air. Hydrochloride stable @ room temperature (in presence of oxygen, oxidn is accelerated by incr temperature). |
| Solubility: | In water, 1,400 mg/L @ 25 deg C /Estimated/ |
| Specification: |
Pharmacology :
Its mechanism of action is not fully understood. Metabolism yields azo-procarbazine and hydrogen peroxide which results in the breaking of DNA strands.
Indications
When Procarbazine (CAS NO.671-16-9) is used to treat Hodgkin's Lymphoma, it is often delivered as part of the MOPP regimen that includes Mechlorethamine, Vincristine (tradename Oncovin), Prednisone, and Procarbazine. Alternatively, when used to treat certain brain tumors (malignant gliomas), it is often dosed as PCV when combined with Lomustine (often called CCNU) and Vincristine.
Procarbazine is also part of the more modern BEACOPP regimen used for Hodgkin's lymphoma.
Side Effects/ Adverse Reactions
When combined with ethanol, Procarbazine (CAS NO.671-16-9) may cause a disulfiram-like reaction in some patients. It also inhibits the liver's CYP450 microsomal system, which leads to an increased effect of barbiturates, phenothiazenes, and narcotics normally metabolized by the CYP450 enzymes. It is also highly carcinogenic—patients have a 5–10% risk of developing acute leukemia, especially in combination with radiation therapy. Has monamine oxidase inhibition properties (MAOI), and should not be taken with most antidepressants and certain migraine medications.
Dose
Adult: 2–4mg/kg/day either in a single dose or divided, given for 7 days then increased to 4–6mg/kg/day until response is obtained or mylosupression occurs. Dose should be adjusted for renal (kidney) disease or hepatic (liver) disease.
|
| Storage Temperature: | Keep in a cool, dry, dark location in a tightly sealed container or cylinder. Keep away from incompatible materials, ignition sources and untrained individuals. Secure and label area. Protect containers/cylinders from physical damage. |
| Usage: | Medication (vet). |
| Safety Data |
| |
 |
